Keros Therapeutics (NASDAQ:KROS) Hits New 52-Week Low – Here’s Why

Keros Therapeutics, Inc. (NASDAQ:KROS) hit a new 52-week low during trading on Wednesday . The stock traded as low as $15.18 and last traded at $15.18, with a volume of 167623 shares traded. The stock had previously closed at $15.84.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Guggenheim cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. Bank of America cut their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Jefferies Financial Group assumed coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Finally, William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $75.00.

Keros Therapeutics Stock Performance

The company’s 50-day simple moving average is $44.38 and its two-hundred day simple moving average is $48.99. The firm has a market cap of $606.39 million, a PE ratio of -2.87 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the company posted ($1.33) EPS. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. On average, analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. KBC Group NV grew its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the period. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after acquiring an additional 1,033 shares in the last quarter. Arizona State Retirement System lifted its stake in shares of Keros Therapeutics by 16.3% in the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares during the period. Finally, Algert Global LLC grew its stake in Keros Therapeutics by 10.6% in the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock worth $717,000 after purchasing an additional 1,505 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.